Can we increase the effectiveness of anti-TNF therapy?

Česká verzia

Authors: M. Bortlík
Authors place of work: Interní klinika 1. LF UK a ÚVN – VFN Praha ; Farmakologický ústav, 1. LF UK a VFN v Praze ; Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in the journal: Gastroent Hepatol 2018; 72(1): 6-7
Category: Editorial

Zdroje

1. Jalali Y, Krajčovičová A, Hlavatý T. Therapeutic drug monitoring in treatment of inflammatory bowel disease with infliximab. Gastroent Hepatol 2018; 72 (1): 41–46. doi: 10.14735/amgh201841.

2. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59 (1): 49–54. doi: 10.1136/gut.2009.183095.

3. Papamichael K, Rivals-Lerebours O, Billiet T et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis 2016; 10 (9): 1015–1023. doi: 10.1093/ecco-jcc/jjw067.

4. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (2): 330–335. doi: 10.1016/j.cgh.2014.07.041.

5. Bortlík M, Ďuricová D, Malíčková K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohn Colitis 2013; 7 (9): 736–743. doi: 10.1016/j.crohns.2012.10.019.

6. Cornillie F, Hanauer SB, Diamond RH et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63 (11): 1721–1727. doi: 10.1136/ gutjnl-2012-304094.

7. Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148 (7): 1320–1329. doi: 10.1053/j.gastro.2015.02. 031.